Lucid Diagnostics officially completed its initial public offering (IPO) in October 2021, transitioning from a private subsidiary of PAVmed into a publicly traded corporation listed on the Nasdaq stock exchange under the ticker symbol LUCD. The public offering raised vital capital to expand its commercial sales infrastructure, support clinical laboratory operations, and accelerate widespread market adoption of its early cancer detection screening tools.